ArrayPlex Selected by Immunome for Targeted Cancer Therapies

ArrayPlex Selected by Immunome for Targeted Cancer Therapies

By, Admin 20 March 2024

Arrayjet’s ArrayPlex™ Platform Has Been Selected by Immunome for Its Discovery of Targeted Cancer Therapies

Overview

Arrayjet, a leading provider of inkjet liquid-handling solutions, has announced that Immunome, Inc. (NASDAQ: IMNM), a biotechnology company focused on developing targeted cancer therapies, has selected its ArrayPlex™ discovery platform to enhance its in-house high-throughput screening capabilities. The ArrayPlex platform, developed by Arrayjet to meet specific assay requirements for high-throughput screening services and tools, will now be accessible to Arrayjet’s screening customers either through its CRO/CMO services or by purchasing an instrument for in-house screening.

Successful Partnership

  • During a successful seven-year partnership, Arrayjet utilized the ArrayPlex platform to perform screening services for Immunome. 
  • Arrayjet has continuously optimized the platform, integrating internal assay controls and enhancing data normalization. 
  • Immunome's decision to acquire an instrument and internalize the ArrayPlex assay underscores its commitment to advancing cancer therapeutic discovery.

Arrayjet’s Inkjet Technology

  • ArrayPlex utilizes Arrayjet’s inkjet technology for bioprinting, enabling the rapid creation of multi-layered assays. 
  • This approach facilitates screening of two libraries against each other for unique binding interactions, generating hits without prior knowledge of either ligand or target at high-throughput rates. 
  • The platform is compatible with various sample types and offers sensitivity comparable to or greater than ELISA.

Words from CEO of Arrayjet

Dr. Iain McWilliam, CEO of Arrayjet, expressed satisfaction with the integration of ArrayPlex into Immunome’s in-house operations, highlighting its potential to advance cancer therapeutic discovery for a broader customer base.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!